{"id":7972,"date":"2020-06-24T12:51:33","date_gmt":"2020-06-24T11:51:33","guid":{"rendered":"https:\/\/www.hgf.com\/?p=7972"},"modified":"2026-02-02T16:22:27","modified_gmt":"2026-02-02T16:22:27","slug":"ip-considerations-in-covid-19-vaccine-development-tensions-and-tools","status":"publish","type":"post","link":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/","title":{"rendered":"IP considerations in COVID-19 vaccine development: tensions and tools"},"content":{"rendered":"<p class=\"p__large\">Development of COVID-19 vaccines will produce valuable IP that could be protected by patents.<\/p>\n<p>However, given that a patent application is not published until about 18 months from its initial filing date, we cannot yet see what kinds of inventions are sought to be covered, who is filing patents, and where patents are being filed to protect COVID-19 related inventions. Given the nature of the pandemic affecting most of the world\u2019s population, its rapid spread and severe complications it causes, some may question whether any IP developed in this area should be subject to protection by private parties to begin with.<\/p>\n<p>HGF Partner Dr Leena Contarino and Senior Patent Attorney Ellie Purnell discuss the perceived tension between patent protection and information sharing at a time of need for collaboration and speed, and suggest that, as evidenced by the Ebola vaccine campaign, patent protection, information sharing, and collaboration are not necessarily mutually exclusive endeavours.<\/p>\n<p>They propose that while some simplified licensing schemes that could be tools to speed up sharing, such as patent pooling initiatives modelled by the telecom and electronics industry are still facing resistance among some pharma companies, development of a better information sharing platform for vaccine technologies could serve as one way to speed up collaborations at time of crises.\u00a0You can read more about COVID-19 licensing challenges\u00a0<a href=\"https:\/\/www.hgf.com\/news\/covid-19-licensing-challenges\/\">here<\/a>.<\/p>\n<p class=\"p__medium\"><a href=\"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/01\/IP-considerations-in-COVID-19-vaccine-development.pdf\">Click here to read the full article<\/a>\u00a0prepared by HGF Partner\u00a0Dr Leena Contarino\u00a0and Senior Patent Attorney\u00a0<a href=\"https:\/\/www.hgf.com\/our-people\/eleanor-purnell\/\">Ellie Purnell<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Development of COVID-19 vaccines will produce valuable IP that could be protected by patents. However, given that a patent application is not published until about 18 months from its initial &hellip;<\/p>\n","protected":false},"author":315,"featured_media":9004111222138422,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[519,518],"tags":[],"class_list":["post-7972","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artikel","category-wissens-hub","sector-arzneimittel","service-patente","sector_groups-life-sciences"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>IP considerations in COVID-19 vaccine development: tensions and tools - HGF<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IP considerations in COVID-19 vaccine development: tensions and tools\" \/>\n<meta property=\"og:description\" content=\"Development of COVID-19 vaccines will produce valuable IP that could be protected by patents. However, given that a patent application is not published\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/\" \/>\n<meta property=\"og:site_name\" content=\"HGF\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-24T11:51:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-02T16:22:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hgf.com\/wp-content\/uploads\/2020\/03\/COVID-19-contractual-and-legal-considerations.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Akvil\u0117 Lukauskaite\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@behrooz@tall.agency\" \/>\n<meta name=\"twitter:site\" content=\"@hgf_ip\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Akvil\u0117 Lukauskaite\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/\"},\"author\":{\"name\":\"Akvil\u0117 Lukauskaite\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/person\\\/e6343663c5ee3e1ccea20cd220f97f30\"},\"headline\":\"IP considerations in COVID-19 vaccine development: tensions and tools\",\"datePublished\":\"2020-06-24T11:51:33+00:00\",\"dateModified\":\"2026-02-02T16:22:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/COVID-19-contractual-and-legal-considerations.jpg\",\"articleSection\":[\"Artikel\",\"Wissens Hub\"],\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/\",\"name\":\"IP considerations in COVID-19 vaccine development: tensions and tools - HGF\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/COVID-19-contractual-and-legal-considerations.jpg\",\"datePublished\":\"2020-06-24T11:51:33+00:00\",\"dateModified\":\"2026-02-02T16:22:27+00:00\",\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/wissens-hub\\\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/COVID-19-contractual-and-legal-considerations.jpg\",\"contentUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/COVID-19-contractual-and-legal-considerations.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/\",\"name\":\"HGF\",\"description\":\"Intellectual Property Rights specialists\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\",\"name\":\"HGF\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/hgf-logo-696x696-1.png\",\"contentUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/hgf-logo-696x696-1.png\",\"width\":696,\"height\":696,\"caption\":\"HGF\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hgf_ip\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hgf-limited-intellectual-property-specialists\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/person\\\/e6343663c5ee3e1ccea20cd220f97f30\",\"name\":\"Akvil\u0117 Lukauskaite\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g\",\"caption\":\"Akvil\u0117 Lukauskaite\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/behrooz@tall.agency\",\"Behrooz Saeed\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IP considerations in COVID-19 vaccine development: tensions and tools - HGF","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/","og_locale":"de_DE","og_type":"article","og_title":"IP considerations in COVID-19 vaccine development: tensions and tools","og_description":"Development of COVID-19 vaccines will produce valuable IP that could be protected by patents. However, given that a patent application is not published","og_url":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/","og_site_name":"HGF","article_published_time":"2020-06-24T11:51:33+00:00","article_modified_time":"2026-02-02T16:22:27+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2020\/03\/COVID-19-contractual-and-legal-considerations.jpg","type":"image\/jpeg"}],"author":"Akvil\u0117 Lukauskaite","twitter_card":"summary_large_image","twitter_creator":"@behrooz@tall.agency","twitter_site":"@hgf_ip","twitter_misc":{"Verfasst von":"Akvil\u0117 Lukauskaite","Gesch\u00e4tzte Lesezeit":"2 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/#article","isPartOf":{"@id":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/"},"author":{"name":"Akvil\u0117 Lukauskaite","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/person\/e6343663c5ee3e1ccea20cd220f97f30"},"headline":"IP considerations in COVID-19 vaccine development: tensions and tools","datePublished":"2020-06-24T11:51:33+00:00","dateModified":"2026-02-02T16:22:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/www.hgf.com\/de\/#organization"},"image":{"@id":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2020\/03\/COVID-19-contractual-and-legal-considerations.jpg","articleSection":["Artikel","Wissens Hub"],"inLanguage":"de-DE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/","url":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/","name":"IP considerations in COVID-19 vaccine development: tensions and tools - HGF","isPartOf":{"@id":"https:\/\/www.hgf.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/#primaryimage"},"image":{"@id":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2020\/03\/COVID-19-contractual-and-legal-considerations.jpg","datePublished":"2020-06-24T11:51:33+00:00","dateModified":"2026-02-02T16:22:27+00:00","inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.hgf.com\/de\/wissens-hub\/ip-considerations-in-covid-19-vaccine-development-tensions-and-tools\/#primaryimage","url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2020\/03\/COVID-19-contractual-and-legal-considerations.jpg","contentUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2020\/03\/COVID-19-contractual-and-legal-considerations.jpg","width":1920,"height":1080},{"@type":"WebSite","@id":"https:\/\/www.hgf.com\/de\/#website","url":"https:\/\/www.hgf.com\/de\/","name":"HGF","description":"Intellectual Property Rights specialists","publisher":{"@id":"https:\/\/www.hgf.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hgf.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.hgf.com\/de\/#organization","name":"HGF","url":"https:\/\/www.hgf.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/04\/hgf-logo-696x696-1.png","contentUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/04\/hgf-logo-696x696-1.png","width":696,"height":696,"caption":"HGF"},"image":{"@id":"https:\/\/www.hgf.com\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hgf_ip","https:\/\/www.linkedin.com\/company\/hgf-limited-intellectual-property-specialists\/"]},{"@type":"Person","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/person\/e6343663c5ee3e1ccea20cd220f97f30","name":"Akvil\u0117 Lukauskaite","image":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/secure.gravatar.com\/avatar\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g","caption":"Akvil\u0117 Lukauskaite"},"sameAs":["https:\/\/x.com\/behrooz@tall.agency","Behrooz Saeed"]}]}},"_links":{"self":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts\/7972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/users\/315"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/comments?post=7972"}],"version-history":[{"count":0,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts\/7972\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/media\/9004111222138422"}],"wp:attachment":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/media?parent=7972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/categories?post=7972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/tags?post=7972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}